

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6921205

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	CELL CURE NEUROSCIENCES LTD.	08/31/2021
RECEIVING PARTY DATA		
Name:	HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.	
Street Address:	JERUSALEM BIOPARK, HADASSAH EIN KEREM MEDICAL CENTER, P.O. BOX 12000	
City:	JERUSALEM	
State/Country:	ISRAEL	
Postal Code:	9112001	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Patent Number:	9658216
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(703) 859-9634	
Email:	martin@ipatent.co.il	
Correspondent Name:	MARTIN MOYNIHAN D/B/A PRTSI, INC.	
Address Line 1:	CUSTOMER NUMBER 67801	
Address Line 2:	232 NW 42ND TER	
Address Line 4:	PLANTATION, FLORIDA 33317	
ATTORNEY DOCKET NUMBER:	60058	
NAME OF SUBMITTER:	MARTIN D. MOYNIHAN	
SIGNATURE:	/Martin D. Moynihan/	
DATE SIGNED:	09/17/2021	
Total Attachments: 2		
source=60058 Executed Assignment from Cell Cure to Hadasit#page1.tif		
source=60058 Executed Assignment from Cell Cure to Hadasit#page2.tif		

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned (hereinafter called the "Assignor"):

Cell Cure Neurosciences Ltd.
P.O. Box 12247
9112102 Jerusalem
Israel

hereby sell(s), assign(s) and transfer(s) to:

Hadasit Medical Research Services and Development Ltd.
Jerusalem BioPark, Hadassah Ein Kerem Medical Center, P.O. Box 12000
9112001 Jerusalem
Israel

(hereinafter called the "Assignee"), its successors, assigns, nominees or other legal representatives, the undersigned's entire rights, title and interest in and to the invention titled:

METHODS OF SELECTING RETINAL PIGMENTED EPITHELIAL CELLS

described and claimed in the following Patent Application:

US Patent No. 9,658,216,
issued on May 23, 2017,
and identified as Attorney Docket No. 60058

and in and to said Patent Application, and all original and reissued Patents granted therefore, and all divisions and continuations thereof, any corresponding PCT Patent Application and the National Phases thereof, including the right to apply and obtain Patents in all other countries, the right to claim priority under International Conventions, and the Letters Patent which may be granted thereon:

covenant that the undersigned have (has) the full right to convey the entire interest therein assigned;

authorize(s) and request(s) the Registrar of Patents, and any Official of any country whose duty it is to issue Patents on applications as aforesaid, to issue the said Letters Patent to the said Assignee;

and agree(s) to sign all lawful papers, make all rightful oaths, do all lawful acts requisite for such Patent Applications, and do everything possible to aid said Assignee to apply for, obtain and enforce Patent protection for said invention.

ASSIGNOR**ASSIGNEE**

Cell Cure Neurosciences Ltd.

Hadasit Medical Research Services and
Development Ltd.

Signature : 

Signature : _____

Name : Brian M. Cullley

Name : _____

Capacity : Chief Executive Officer

Capacity : _____

Date : AUGUST 31, 2024

Date : _____

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned (hereinafter called the "Assignor"):

Cell Cure Neurosciences Ltd.
P.O. Box 12247
9112102 Jerusalem
Israel

hereby sell(s), assign(s) and transfer(s) to:

Hadasit Medical Research Services and Development Ltd.
Jerusalem BioPark, Hadassah Ein Kerem Medical Center, P.O. Box 12000
9112001 Jerusalem
Israel

(hereinafter called the "Assignee"), its successors, assigns, nominees or other legal representatives, the undersigned's entire rights, title and interest in and to the invention titled:

METHODS OF SELECTING RETINAL PIGMENTED EPITHELIAL CELLS

described and claimed in the following Patent Application:

US Patent No. 9,658,216,
issued on May 23, 2017,
and identified as Attorney Docket No. 60058

and in and to said Patent Application, and all original and reissued Patents granted therefore, and all divisions and continuations thereof, any corresponding PCT Patent Application and the National Phases thereof, including the right to apply and obtain Patents in all other countries, the right to claim priority under International Conventions, and the Letters Patent which may be granted thereon:

covenant that the undersigned have (has) the full right to convey the entire interest therein assigned;

authorize(s) and request(s) the Registrar of Patents, and any Official of any country whose duty it is to issue Patents on applications as aforesaid, to issue the said Letters Patent to the said Assignee;

and agree(s) to sign all lawful papers, make all rightful oaths, do all lawful acts requisite for such Patent Applications, and do everything possible to aid said Assignee to apply for, obtain and enforce Patent protection for said invention.

ASSIGNOR

Cell Cure Neurosciences Ltd.

Signature : _____


Name : _____

Capacity : _____

Date : _____

ASSIGNEE

Hadasit Medical Research Services and
Development Ltd.

Signature :  **DR. TAMAR RAZ**
CEO
Hadasit Medical Research Services
& Development Ltd.

Name : Dr. Tamar Raz

Capacity : CEO

Date : September 13, 2021

PATENT